GENE-IQ Announces Expanded Capacity for COVID-19 Testing
State-of-the-art Testing Designed to Safeguard Individuals and Businesses
DALLAS–(BUSINESS WIRE)–#PCRcovid19test–GENE-IQ announces its new expanded capacity for its real-time reverse transcriptase polymerase chain reaction (rRT-PCR) based testing for COVID-19. The CLIA certified high-complexity diagnostics laboratory adheres to the highest standards in molecular testing, ensuring timely, actionable and accurate delivery of test results to guide patient care.
Frank G Howard, Chief Executive Officer of GENE-IQ stated, “By bolstering our staff and infrastructure, we are now well-positioned to provide an additional five thousand tests per day to help safely reopen the country. We utilize rRT-PCR, which is considered the gold standard in testing for COVID-19. When combined with social distancing, proper sanitation and personal hygiene, this test can help ensure the safety of workers, physicians, patients and their family members.”
The GENE-IQ testing methodology combines automation and artificial intelligence to achieve industry leading throughput and accuracy. It employs a non-invasive nasal-swab collection methodology that can be easily self-administered. After a sample is collected, the nasal swab is placed in a bar-coded collection tube and overnighted to GENE-IQ for analysis. The results are provided within 24-48 hours via a Health Insurance Portability and Accountability Act (HIPAA) compliant portal.
The company serves assisted living facilities, long-term care communities, hospitals, surgical centers, medical practices, and corporations needing to maintain safe workplace environments.
Located in The Colony, Texas, GENE-IQ’s diagnostics laboratory provides a multifaceted testing portfolio. It focuses on pharmacogenomic testing, cancer genomic testing, and infectious disease testing for respiratory, urinary and COVID-19 pathogens. Pharmacogenomic testing (PGx) analyzes an individual’s DNA to predict how they metabolize medications, while cancer genomic testing (CGx) analyzes an individual’s DNA to predict their predisposition to hereditary cancers.
The state-of-the-art laboratory works with large commercial employers, institutions, medical providers and facilities to establish broad testing programs to safeguard their individuals and businesses.
John Harris: firstname.lastname@example.org 480-381-9893